Want to see JP:4925 full AI Analyst Report?
Top Page
HABA Laboratories, Inc.
(4925)
Select Model
Select Model
Rating:74Outperform
Price Target:
¥1,962.00
▲(13.61% Upside)
Action:Upgraded
Date:08/17/26
The score is driven primarily by improving financial performance (turnaround to profitability, low leverage, and solid recent cash generation) and supportive valuation (low P/E plus dividend yield). Technical indicators add a modest tailwind as the stock trades above key moving averages with positive MACD, but momentum signals are not strongly bullish.
Positive Factors
Profitability Turnaround
The return to profitability, supported by consistently high gross margins, indicates improved operating economics and product-level resilience. If maintained, this creates a stronger base for reinvestment and more dependable earnings over the next several quarters.
Negative Factors
Modest Net Margin
The gap between strong gross margins and a modest net margin suggests operating expenses and other costs absorb much of the value created at the product level. This leaves limited earnings cushion if costs rise or demand weakens.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability Turnaround
The return to profitability, supported by consistently high gross margins, indicates improved operating economics and product-level resilience. If maintained, this creates a stronger base for reinvestment and more dependable earnings over the next several quarters.
Read all positive factors
HABA Laboratories, Inc. (4925) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.53B
Dividend Yield2.32%
Average Volume (3M)2.14K
Price to Earnings (P/E)9.6
Beta (1Y)0.27
Revenue Growth0.16%
EPS Growth6.35%
CountryJP
Employees523
SectorGeneral
Sector StrengthN/A
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)201.07
Shares Outstanding3,935,000
10 Day Avg. Volume2,940
30 Day Avg. Volume2,136
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)0.67
Price to Sales (P/S)0.53
P/FCF Ratio5.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HABA Laboratories, Inc. Business Overview & Revenue Model
Company Description
Established in Tokyo, Japan, in 1983, HABA Laboratories, Inc. develops and distributes a comprehensive range of skincare, hair, and body care items both domestically and across international markets. Their skincare portfolio encompasses facial cle...
How the Company Makes Money
null...
HABA Laboratories, Inc. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 12.14B | 12.06B | 12.32B | 12.04B | 12.91B |
| Gross Profit | 7.95B | 7.99B | 8.03B | 8.17B | 8.79B |
| EBITDA | 898.40M | 811.56M | -1.31B | 17.05M | 448.30M |
| Net Income | 760.36M | 576.57M | -2.12B | -707.87M | -269.03M |
Balance Sheet | |||||
| Total Assets | 12.52B | 12.34B | 12.43B | 14.73B | 15.76B |
| Cash, Cash Equivalents and Short-Term Investments | 5.78B | 4.74B | 3.96B | 4.82B | 5.65B |
| Total Debt | 1.19B | 1.82B | 2.36B | 2.03B | 2.56B |
| Total Liabilities | 2.98B | 3.42B | 3.92B | 3.96B | 4.12B |
| Stockholders Equity | 9.54B | 8.93B | 8.51B | 10.77B | 11.64B |
Cash Flow | |||||
| Free Cash Flow | 1.16B | 1.48B | -1.02B | -232.69M | 1.53B |
| Operating Cash Flow | 1.24B | 1.62B | -587.92M | 55.96M | 1.71B |
| Investing Cash Flow | 484.54M | -147.18M | -441.79M | -214.40M | -216.49M |
| Financing Cash Flow | -780.75M | -689.49M | 171.06M | -676.32M | -1.51B |
HABA Laboratories, Inc. Technical Analysis
Neutral
1727.00
Price Trends
1731.86
Negative
1719.78
Positive
1704.43
Positive
Market Momentum
-4.51
Positive
43.72
Neutral
47.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4925, the sentiment is Neutral. The current price of 1727 is below the 20-day moving average (MA) of 1739.10, below the 50-day MA of 1731.86, and above the 200-day MA of 1704.43, indicating a neutral trend. The MACD of -4.51 indicates Positive momentum. The RSI at 43.72 is Neutral, neither overbought nor oversold. The STOCH value of 47.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4925.
HABA Laboratories, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ¥6.53B | 9.60 | ― | 2.29% | 0.16% | 6.35% | |
70 Outperform | ¥26.28B | 11.75 | ― | 0.91% | 13.71% | -16.12% | |
65 Neutral | ¥5.35B | 29.17 | ― | 1.68% | 3.17% | -27.27% | |
59 Neutral | ¥1.71B | 8.86 | ― | ― | -6.17% | -55.84% | |
58 Neutral | ¥7.79B | 43.01 | ― | 2.82% | 0.96% | -28.27% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ¥2.33B | 6.83 | ― | 2.70% | 3.05% | 184.11% |
* General Sector Average
JP:4925
HABA Laboratories, Inc.
1,727.00
16.87
0.99%
JP:4918
Ivy Cosmetics Corporation
302.00
2.34
0.78%
JP:4920
Nippon Shikizai, Inc.
1,114.00
82.07
7.95%
JP:4926
C'BON COSMETICS Co., Ltd.
1,250.00
64.80
5.47%
JP:4933
I-ne CO., LTD.
1,477.00
-84.83
-5.43%
JP:4936
AXXZIA, Inc.
323.00
-120.88
-27.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.